Programme National DE Lutte

Programme National DE Lutte (PNL) is a government-led initiative in Côte d'Ivoire, primarily focused on combating infectious diseases, notably malaria. As a public health program, PNL operates under the Ministry of Health and Public Hygiene, coordinating national efforts to prevent and treat malaria through various interventions, including the procurement and distribution of pharmaceutical products. While not a commercial entity, PNL functions as a central buyer and distributor, sourcing essential medications to ensure nationwide availability. Its role is pivotal in the pharmaceutical supply chain, particularly in the antimalarial sector, where it collaborates with both local and international suppliers to meet the country's health needs.

PNL's distribution network is strategically designed to ensure the efficient delivery of antimalarial medications across Côte d'Ivoire. The program collaborates with regional health authorities and local pharmacies to facilitate the widespread availability of treatments. While specific warehouse locations and logistics capabilities are not publicly detailed, PNL's operations are integrated with the national health infrastructure, leveraging existing facilities and transportation networks to reach both urban and rural areas. This integration ensures that antimalarial drugs are accessible to the entire population, aligning with the program's mission to combat malaria effectively.

In Côte d'Ivoire's pharmaceutical supply chain, PNL serves as a primary wholesaler and distributor, focusing exclusively on antimalarial and antiparasitic medications. By centralizing the procurement and distribution of these essential drugs, PNL plays a critical role in standardizing treatment protocols and ensuring equitable access across the country. Its operations are distinct from commercial importers, as PNL's activities are driven by public health objectives rather than profit motives, emphasizing the importance of malaria control in national health policy.

PNL's sourcing strategy exhibits a high degree of concentration, importing two primary products—Pyrimethamine and Sulfadoxine—each valued at $100,000 USD, accounting for 50% of its total imports from India. This focus on two antimalarial agents suggests a strategic choice to streamline procurement and ensure consistent supply. The program's reliance on a limited number of products may enhance negotiation leverage with suppliers and simplify logistics. However, this concentration also poses risks; any disruptions in the supply chain for these specific medications could significantly impact PNL's ability to meet national demand. The stability of PNL's relationships with its Indian suppliers is crucial, as evidenced by the program's engagement with multiple suppliers, which may provide a buffer against potential supply chain disruptions.

PNL's supply chain resilience is bolstered by its engagement with multiple Indian pharmaceutical suppliers, including MACLEODS PHARMACEUTICALS LIMITED, IPCA LABORATORIES LIMITED, and MYLAN LABORATORIES LIMITED. This diversified supplier base mitigates the risks associated with single-source dependency, enhancing the program's ability to maintain a steady supply of antimalarial medications. The importation of 64 unique formulations indicates a strategic approach to sourcing, allowing PNL to adapt to varying treatment protocols and patient needs. While the program's focus on finished pharmaceutical formulations from India suggests a reliance on international suppliers, it also reflects a commitment to quality and efficacy, as these suppliers are subject to stringent regulatory standards. PNL's adherence to Côte d'Ivoire's regulatory requirements, including obtaining necessary import authorizations and ensuring compliance with good manufacturing practices, further strengthens the resilience of its supply chain.

PNL's concentrated sourcing pattern positions it as a significant player in the antimalarial medication market within Côte d'Ivoire. For Indian exporters, this presents an opportunity to establish or strengthen partnerships with PNL, given the program's substantial procurement volume. Suppliers that can offer consistent quality, competitive pricing, and reliable delivery schedules are well-positioned to meet PNL's needs. Additionally, PNL's focus on antimalarial and antiparasitic drugs aligns with India's robust pharmaceutical manufacturing capabilities in these therapeutic areas, suggesting a strategic fit for potential suppliers. However, the high concentration of PNL's imports also means that any changes in the program's procurement strategy or shifts in supplier relationships could have a significant impact on individual exporters.

In Côte d'Ivoire, the regulation of pharmaceutical products is overseen by the Ivorian Pharmaceutical Regulatory Authority (AIRP), established under Law No. 2017-541 of 3 August 2017. This law provides the institutional and functional framework for the pharmaceutical sector, ensuring the availability of accessible, safe, effective, and high-quality pharmaceutical products. The AIRP is responsible for issuing import and export authorizations, monitoring compliance with good manufacturing practices, and enforcing regulations related to pharmaceutical products. For the importation of pharmaceutical products, including antimalarial medications, importers must obtain an Official Import Authorization (OIA) from the AIRP prior to shipment. This authorization process involves submitting an application that includes a pro forma invoice, a list of products to be imported, and other relevant documentation. The AIRP's role is critical in maintaining the integrity of the pharmaceutical supply chain and ensuring that imported products meet the country's health standards. (gucecotedivoire.ci)

Import licensing in Côte d'Ivoire is governed by the AIRP, which requires importers to obtain an Official Import Authorization (OIA) before shipping pharmaceutical products into the country. The application for an OIA must include a pro forma invoice, a list of products to be imported, and other pertinent documents. Additionally, importers must ensure that their products comply with good manufacturing practices (GMP) recognized by international standards, such as EU GMP, WHO GMP, or PIC/S. This compliance is essential for the registration and approval of pharmaceutical products in Côte d'Ivoire. Furthermore, importers must obtain a wholesale distribution authorization, which involves meeting specific regulatory requirements set by the AIRP to ensure the safe and effective distribution of pharmaceutical products within the country. (gucecotedivoire.ci)

Imported pharmaceutical products in Côte d'Ivoire must undergo batch testing to ensure they meet the country's health and safety standards. This testing is typically conducted by the manufacturer or a recognized third-party laboratory and must be documented in a certificate of analysis or certificate of conformity. The labeling of pharmaceutical products must be in French, the official language of Côte d'Ivoire, and must include essential information such as the product name, dosage form, strength, batch number, expiry date, and storage conditions. Serialization mandates may apply to facilitate traceability and prevent counterfeit products; however, specific requirements should be verified with the AIRP. Compliance with these quality and labeling standards is crucial for the registration and importation of pharmaceutical products into Côte d'Ivoire. (gucecotedivoire.ci)

Between 2024 and 2026, Côte d'Ivoire has implemented several regulatory changes affecting the importation of pharmaceutical products. Notably, the introduction of the Official Import Authorization (OIA) process by the AIRP has streamlined the import authorization procedure, requiring importers to submit a comprehensive application that includes a pro forma invoice, a list of products to be imported, and other relevant documentation. Additionally, the AIRP has emphasized the need for compliance with international good manufacturing practices (GMP), such as EU GMP, WHO GMP, or PIC/S, for the registration and approval of pharmaceutical products. These changes aim to enhance the quality and safety of imported pharmaceutical products and align Côte d'Ivoire's regulatory framework with international standards. (gucecotedivoire.ci)

PNL's focus on antimalarial and antiparasitic medications aligns with the high prevalence of malaria in Côte d'Ivoire, where the disease remains a leading cause of morbidity and mortality. The program's procurement strategy is driven by the need to provide effective and accessible treatments to the population, ensuring that both urban and rural communities have access to essential antimalarial drugs. By concentrating on these therapeutic areas, PNL aims to reduce the burden of malaria through consistent and widespread distribution of medications, thereby contributing to the country's public health objectives.

PNL's sourcing strategy is centered on importing finished pharmaceutical formulations from India, a country renowned for its robust pharmaceutical manufacturing sector. This approach allows PNL to leverage India's expertise in producing high-quality antimalarial and antiparasitic medications. The program's focus on finished formulations indicates a preference for ready-to-use products, facilitating efficient distribution and minimizing the complexities associated with raw material imports. India's established regulatory standards and competitive pricing further enhance its suitability as a sourcing partner for PNL.

PNL serves the public health sector in Côte d'Ivoire, focusing on the distribution of antimalarial and antiparasitic medications. Its operations are distinct from commercial entities, as PNL's activities are driven by public health objectives rather than profit motives. By centralizing the procurement and distribution of these essential drugs, PNL ensures equitable access across the country, aligning with national health policies aimed at controlling and eliminating malaria.

For new Indian suppliers, there is a realistic opportunity to engage with PNL, given the program's substantial procurement volume and its